Last reviewed · How we verify

Ro 65-5788 — Competitive Intelligence Brief

Ro 65-5788 (Ceftobiprole medocaril) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ceftobiprole medocaril. Area: Infectious Disease.

discontinued ceftobiprole medocaril Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ro 65-5788 (Ceftobiprole medocaril) — Advanz. Ceftobiprole medocaril works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ro 65-5788 TARGET Ceftobiprole medocaril Advanz discontinued ceftobiprole medocaril

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ceftobiprole medocaril class)

  1. Advanz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ro 65-5788 — Competitive Intelligence Brief. https://druglandscape.com/ci/ceftobiprole-medocaril. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: